Home › Companies › IMMUNOVANT INC. › 2024-2025
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and IMMUNOVANT INC.’s Form 8-K, filed August 13, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of August 12, 2024: 5 items on IMMUNOVANT INC.’s Form 8-K, filed August 13, 2024: 2 elected · 2 approved · 1 passed (calculated).
Significant dissent: 3 directors (26.3%, 25.6%, 24.2% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Proxy season: 2023-2024 2024-2025 2025-2026
Activist investors: Two Seas Capital LP (13F, 2.2%, as of September 30, 2026)
Explore IMMUNOVANT INC. in the interactive database Compare manager voting policies
These tallies are IMMUNOVANT INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed August 13, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Peter Salzmann, M.D., M.B.A. | 99,849,994 | -- | -- | 31,897,811 | 6,513,760 | 76% | Passed (calculated) | — |
| Elect Director: George Migausky | 98,023,809 | -- | -- | 33,723,996 | 6,513,760 | 74% | Elected | — |
| Elect Director: Douglas Hughes | 97,129,496 | -- | -- | 34,618,309 | 6,513,760 | 74% | Elected | — |
| 2. Ratification of the Selection of Independent Registered Public Accounting Firm | 138,241,628 | 16,740 | 3,197 | -- | -- | 99.9% | Approved | — |
| 3. Approval, on a Non-Binding Advisory Basis, of the Compensation of Immunovant's Named Executive Officers | 128,494,310 | 3,249,170 | 4,325 | -- | 6,513,760 | 98% | Approved | — |
Source: IMMUNOVANT INC., Form 8-K, filed with the SEC on August 13, 2024 — read the filing on EDGAR.
See voting trends for Health Care companies, 2024-2025: shareholder support by sector and by company size.
226 asset managers disclosed a vote on at least one IMMUNOVANT INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 4 wordings of this item as funds reported it.
74% Majority: yes · of votes cast
Prior year: 83.1% for (August 21, 2023 meeting) ▼ 9.4 pts
Description as filed by funds: To elect as directors the three nominees named in the Company's proxy statement, each to hold office until our 2025 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Douglas Hughes
IMMUNOVANT INC.’s own tally for this item (“Elect Director: Douglas Hughes”): 97,129,496 for, 34,618,309 withheld, per its Form 8-K filed August 13, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1 – Election of Directors Peter Salzmann, M.D., M.B.A., George Migausky and Douglas Hughes were each elected to serve as a member of Immunovant's Board of Directors (the "Board"), until the 2025 Annual Meeting of Stockholders and until his successor is duly elected and qualified, or until …”
Support: 74% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 76 asset managers below reported 8,395,082 for, 15,738,953 withheld, 2,336,986 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 0 | 0 | 0 | 7,338,989 | Withhold |
| Vanguard | 6,304,664 | 0 | 0 | 0 | For |
| State Street | 2,202 | 0 | 0 | 2,117,777 | Withhold |
| T. Rowe Price | 0 | 0 | 0 | 2,114,983 | Withhold |
| BlackRock | 0 | 0 | 1,768,466 | 0 | Abstain |
| Capital Group | 976,237 | 0 | 0 | 0 | For |
| TIAA | 0 | 0 | 0 | 861,221 | Withhold |
| ALGER FUNDS | 0 | 0 | 0 | 496,198 | Withhold |
| Charles Schwab | 448,502 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 0 | 0 | 400,722 | Withhold |
| Invesco | 0 | 0 | 0 | 361,064 | Withhold |
| FRANKLIN STRATEGIC SERIES | 325,213 | 0 | 0 | 0 | For |
| Principal | 0 | 0 | 0 | 268,304 | Withhold |
| Victory Capital | 0 | 0 | 0 | 237,974 | Withhold |
| Jackson National | 99,699 | 0 | 88,499 | 0 | Mixed |
| Dimensional | 0 | 0 | 0 | 164,319 | Withhold |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 163,407 | Withhold |
| Equitable | 0 | 0 | 0 | 140,918 | Withhold |
| Nuveen | 0 | 0 | 0 | 132,676 | Withhold |
| Delaware/Macquarie | 0 | 0 | 0 | 122,100 | Withhold |
| Bridge Builder Trust | 0 | 0 | 118,494 | 0 | Abstain |
| Russell Investments | 109,695 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 0 | 0 | 102,304 | 0 | Abstain |
| JPMorgan | 0 | 0 | 88,871 | 0 | Abstain |
| FINANCIAL INVESTORS TRUST | 0 | 0 | 88,339 | 0 | Abstain |
Showing the 25 largest of 76 asset managers. All 76 are in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
74% Majority: yes · of votes cast
Prior year: 83.1% for (August 21, 2023 meeting) ▼ 8.7 pts
Description as filed by funds: To elect as directors the three nominees named in the Company's proxy statement, each to hold office until our 2025 Annual Meeting of Stockholders and until their successors are duly elected and qualified: George Migausky
IMMUNOVANT INC.’s own tally for this item (“Elect Director: George Migausky”): 98,023,809 for, 33,723,996 withheld, per its Form 8-K filed August 13, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1 – Election of Directors Peter Salzmann, M.D., M.B.A., George Migausky and Douglas Hughes were each elected to serve as a member of Immunovant's Board of Directors (the "Board"), until the 2025 Annual Meeting of Stockholders and until his successor is duly elected and qualified, or until …”
Support: 74% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 76 asset managers below reported 8,878,064 for, 15,255,971 withheld, 2,336,986 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 0 | 0 | 0 | 7,338,989 | Withhold |
| Vanguard | 6,304,664 | 0 | 0 | 0 | For |
| State Street | 2,202 | 0 | 0 | 2,117,777 | Withhold |
| T. Rowe Price | 0 | 0 | 0 | 2,114,983 | Withhold |
| BlackRock | 0 | 0 | 1,768,466 | 0 | Abstain |
| Capital Group | 976,237 | 0 | 0 | 0 | For |
| TIAA | 0 | 0 | 0 | 861,221 | Withhold |
| ALGER FUNDS | 0 | 0 | 0 | 496,198 | Withhold |
| Charles Schwab | 448,502 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 0 | 0 | 400,722 | Withhold |
| Invesco | 361,064 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 325,213 | 0 | 0 | 0 | For |
| Principal | 147 | 0 | 0 | 268,157 | Withhold |
| Victory Capital | 0 | 0 | 0 | 237,974 | Withhold |
| Jackson National | 99,699 | 0 | 88,499 | 0 | Mixed |
| Dimensional | 0 | 0 | 0 | 164,319 | Withhold |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 163,407 | Withhold |
| Equitable | 0 | 0 | 0 | 140,918 | Withhold |
| Nuveen | 0 | 0 | 0 | 132,676 | Withhold |
| Delaware/Macquarie | 0 | 0 | 0 | 122,100 | Withhold |
| Bridge Builder Trust | 0 | 0 | 118,494 | 0 | Abstain |
| Russell Investments | 109,695 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 0 | 0 | 102,304 | 0 | Abstain |
| JPMorgan | 0 | 0 | 88,871 | 0 | Abstain |
| FINANCIAL INVESTORS TRUST | 0 | 0 | 88,339 | 0 | Abstain |
Showing the 25 largest of 76 asset managers. All 76 are in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
76% Majority: yes · of votes cast
Prior year: 84.8% for (August 21, 2023 meeting) ▼ 9.0 pts
Description as filed by funds: To elect as directors the three nominees named in the Company's proxy statement, each to hold office until our 2025 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Peter Salzmann, M.D., M.B.A.
IMMUNOVANT INC.’s own tally for this item (“Elect Director: Peter Salzmann, M.D., M.B.A.”): 99,849,994 for, 31,897,811 withheld, per its Form 8-K filed August 13, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 76% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 76 asset managers below reported 7,627,159 for, 18,489,206 withheld, 354,656 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 24,862 | 0 | 0 | 7,314,127 | Withhold |
| Vanguard | 0 | 0 | 0 | 6,304,664 | Withhold |
| State Street | 2,117,232 | 0 | 0 | 2,747 | For |
| T. Rowe Price | 1,109,309 | 0 | 0 | 1,005,674 | Mixed |
| BlackRock | 1,768,466 | 0 | 0 | 0 | For |
| Capital Group | 976,237 | 0 | 0 | 0 | For |
| TIAA | 0 | 0 | 0 | 861,221 | Withhold |
| ALGER FUNDS | 0 | 0 | 0 | 496,198 | Withhold |
| Charles Schwab | 448,502 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 0 | 0 | 400,722 | Withhold |
| Invesco | 0 | 0 | 0 | 361,064 | Withhold |
| FRANKLIN STRATEGIC SERIES | 325,213 | 0 | 0 | 0 | For |
| Principal | 147 | 0 | 0 | 268,157 | Withhold |
| Victory Capital | 0 | 0 | 0 | 237,974 | Withhold |
| Jackson National | 99,699 | 0 | 88,499 | 0 | Mixed |
| Dimensional | 0 | 0 | 0 | 164,319 | Withhold |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 163,407 | Withhold |
| Equitable | 85,268 | 0 | 0 | 55,650 | Mixed |
| Nuveen | 0 | 0 | 0 | 132,676 | Withhold |
| Delaware/Macquarie | 0 | 0 | 0 | 122,100 | Withhold |
| Bridge Builder Trust | 10,052 | 0 | 108,442 | 0 | Mixed |
| Russell Investments | 109,695 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 102,304 | 0 | 0 | 0 | For |
| JPMorgan | 88,871 | 0 | 0 | 0 | For |
| FINANCIAL INVESTORS TRUST | 0 | 0 | 88,339 | 0 | Abstain |
Showing the 25 largest of 76 asset managers. All 76 are in the interactive database (link above).
Combines 8 wordings of this item as funds reported it.
98% Approved · of votes cast
Prior year: 99.3% for (August 21, 2023 meeting) ▼ 1.8 pts
Description as filed by funds: To approve, on a non-binding, advisory basis, the compensation of our named executive officers.
IMMUNOVANT INC.’s own tally for this item (“3. Approval, on a Non-Binding Advisory Basis, of the Compensation of Immunovant's Named Executive Officers”): 128,494,310 for, 3,249,170 against — passed, per its Form 8-K filed August 13, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 3 - Approval, on a Non-Binding Advisory Basis, of the Compensation of Immunovant's Named Executive Officers The stockholders approved, on a non-binding advisory basis, the compensation of Immunovant's named executive officers, as disclosed in the Proxy Statement, including the compensation…”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 7,338,989 | 0 | 0 | 0 | For |
| Vanguard | 6,304,664 | 0 | 0 | 0 | For |
| State Street | 2,119,539 | 440 | 0 | 0 | For |
| T. Rowe Price | 2,114,983 | 0 | 0 | 0 | For |
| BlackRock | 1,768,466 | 0 | 0 | 0 | For |
| Capital Group | 0 | 976,237 | 0 | 0 | Against |
| TIAA | 861,221 | 0 | 0 | 0 | For |
| ALGER FUNDS | 0 | 496,198 | 0 | 0 | Against |
| Charles Schwab | 448,502 | 0 | 0 | 0 | For |
| Aberdeen | 400,722 | 0 | 0 | 0 | For |
| Invesco | 0 | 361,064 | 0 | 0 | Against |
| FRANKLIN STRATEGIC SERIES | 325,213 | 0 | 0 | 0 | For |
| Principal | 268,304 | 0 | 0 | 0 | For |
| Victory Capital | 237,974 | 0 | 0 | 0 | For |
| Jackson National | 188,198 | 0 | 0 | 0 | For |
| Dimensional | 164,319 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 163,407 | 0 | 0 | 0 | For |
| Equitable | 140,918 | 0 | 0 | 0 | For |
| Nuveen | 132,676 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 122,100 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 118,494 | 0 | 0 | 0 | For |
| Russell Investments | 109,695 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 102,304 | 0 | 0 | 0 | For |
| JPMorgan | 88,871 | 0 | 0 | 0 | For |
| FINANCIAL INVESTORS TRUST | 88,339 | 0 | 0 | 0 | For |
Fund voting reports, all 75 managers: 24,423,978 for, 1,998,948 against, 2,595 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 10,291,429 | 0 | 0 | 0 | For |
| State Street | 3,155,075 | 609 | 0 | 0 | For |
| T. Rowe Price | 2,918,007 | 0 | 0 | 0 | For |
| VIKING GLOBAL INVESTORS LP | 2,317,402 | 0 | 0 | 0 | For |
| Deep Track Capital, LP | 1,981,490 | 0 | 0 | 0 | For |
| BlackRock | 1,805,459 | 11,397 | 0 | 0 | For |
| ARMISTICE CAPITAL, LLC | 1,686,825 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,330,501 | 0 | 0 | 0 | For |
| Rock Springs Capital Management LP | 1,167,694 | 0 | 0 | 0 | For |
| PICTET ASSET MANAGEMENT SA | 1,133,782 | 0 | 0 | 0 | For |
| Nuveen | 1,052,445 | 0 | 0 | 0 | For |
| Capital Research Global Investors | 0 | 976,237 | 0 | 0 | Against |
| FRANKLIN ADVISERS INC | 960,229 | 0 | 0 | 0 | For |
| Boxer Capital Management, LLC | 825,000 | 0 | 0 | 0 | For |
| Paradigm Biocapital Advisors LP | 804,771 | 0 | 0 | 0 | For |
| Commodore Capital LP | 750,990 | 0 | 0 | 0 | For |
| Logos Global Management LP | 720,501 | 0 | 0 | 0 | For |
| Redmile Group, LLC | 666,704 | 0 | 0 | 0 | For |
| FRED ALGER MANAGEMENT, LLC | 0 | 612,865 | 0 | 0 | Against |
| Invesco | 0 | 460,304 | 0 | 0 | Against |
| Charles Schwab | 448,503 | 0 | 0 | 0 | For |
| Victory Capital | 402,816 | 0 | 0 | 0 | For |
| Aberdeen | 400,722 | 0 | 0 | 0 | For |
| Northern Trust | 359,027 | 0 | 0 | 0 | For |
| PFM Health Sciences, LP | 349,915 | 0 | 0 | 0 | For |
Institutional-manager reports, all 172 managers: 40,165,606 for, 2,687,602 against, 45,500 withheld. Showing the 25 largest; every one is in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
99.9% Approved · of votes cast
Prior year: 100.0% for (August 21, 2023 meeting) unchanged
Description as filed by funds: To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending March 31, 2025.
IMMUNOVANT INC.’s own tally for this item (“2. Ratification of the Selection of Independent Registered Public Accounting Firm”): 138,241,628 for, 16,740 against — passed, per its Form 8-K filed August 13, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 2 – Ratification of the Selection of Independent Registered Public Accounting Firm The stockholders ratified the selection by the Audit Committee of the Board of Ernst & Young LLP as Immunovant's independent registered public accounting firm for the fiscal year ending March 31, 2025, by th…”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 76 asset managers below reported 26,468,197 for, 229 against, 2,595 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 7,338,989 | 0 | 0 | 0 | For |
| Vanguard | 6,304,664 | 0 | 0 | 0 | For |
| State Street | 2,119,979 | 0 | 0 | 0 | For |
| T. Rowe Price | 2,114,983 | 0 | 0 | 0 | For |
| BlackRock | 1,768,466 | 0 | 0 | 0 | For |
| Capital Group | 976,237 | 0 | 0 | 0 | For |
| TIAA | 861,221 | 0 | 0 | 0 | For |
| ALGER FUNDS | 496,198 | 0 | 0 | 0 | For |
| Charles Schwab | 448,502 | 0 | 0 | 0 | For |
| Aberdeen | 400,722 | 0 | 0 | 0 | For |
| Invesco | 361,064 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 325,213 | 0 | 0 | 0 | For |
| Principal | 268,304 | 0 | 0 | 0 | For |
| Victory Capital | 237,974 | 0 | 0 | 0 | For |
| Jackson National | 188,198 | 0 | 0 | 0 | For |
| Dimensional | 164,319 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 163,407 | 0 | 0 | 0 | For |
| Equitable | 140,918 | 0 | 0 | 0 | For |
| Nuveen | 132,676 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 122,100 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 118,494 | 0 | 0 | 0 | For |
| Russell Investments | 109,695 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 102,304 | 0 | 0 | 0 | For |
| JPMorgan | 88,871 | 0 | 0 | 0 | For |
| FINANCIAL INVESTORS TRUST | 88,339 | 0 | 0 | 0 | For |
Showing the 25 largest of 76 asset managers. All 76 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 146,195,673 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 5.02% |
| 2 | Vanguard | 4.31% |
| 3 | State Street | 1.45% |
| 4 | T. Rowe Price | 1.45% |
| 5 | BlackRock | 1.21% |
| 6 | Capital Group | 0.67% |
| 7 | TIAA | 0.59% |
| 8 | ALGER FUNDS | 0.34% |
| 9 | Charles Schwab | 0.31% |
| 10 | Aberdeen | 0.27% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 7.04% |
| 2 | State Street | 2.16% |
| 3 | T. Rowe Price | 2.00% |
| 4 | VIKING GLOBAL INVESTORS LP | 1.59% |
| 5 | Deep Track Capital, LP | 1.36% |
| 6 | BlackRock | 1.24% |
| 7 | ARMISTICE CAPITAL, LLC | 1.15% |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 0.91% |
| 9 | Rock Springs Capital Management LP | 0.80% |
| 10 | PICTET ASSET MANAGEMENT SA | 0.78% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| Roivant Sciences Ltd. | 113,327,007 | — | Schedule 13D, filed December 12, 2025 |
| FMR (Fidelity) | 17,241,035 | — | Form 13F, quarter ended March 31, 2025 |
| FMR LLC | 17,078,093 | — | Proxy statement (DEF 14A), proxy filed July 9, 2025 |
| Entities affiliated with Deep Track Capital, LP | 9,500,000 | — | Proxy statement (DEF 14A), proxy filed July 9, 2025 |
| Vanguard Group | 6,936,859 | — | Form 13F, quarter ended March 31, 2025 |
| BlackRock | 5,364,222 | — | Form 13F, quarter ended March 31, 2025 |
| Peter Salzmann, M.D. | 3,646,913 | — | Proxy statement (DEF 14A), proxy filed July 9, 2025 |
| State Street | 3,087,095 | — | Form 13F, quarter ended March 31, 2025 |
| Frank M. Torti, M.D. | 1,710,833 | — | Proxy statement (DEF 14A), proxy filed July 9, 2025 |
| Geode Capital | 1,672,590 | — | Form 13F, quarter ended March 31, 2025 |
Percentages above are of 146,195,673 shares outstanding, as reported by IMMUNOVANT INC. on its Form 10-Q dated June 30, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At IMMUNOVANT INC.'s shareholder meeting held August 12, 2024, in the 2024-2025 proxy season, 226 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 1,417 separate fund positions. On the most widely held item on that ballot — To approve, on a non-binding, advisory basis, the compensation of our named executive officers. — IMMUNOVANT INC.'s filing reports the proposal as approved, with 98% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: IMMUNOVANT INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on August 13, 2024.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from IMMUNOVANT INC.’s 10-Q dated June 30, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
IMMUNOVANT INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.
Proxy Votes Now, “IMMUNOVANT (IMVT) 2024 Annual Meeting (2024-2025 season): Vote Results”, https://proxyvotesnow.com/company/immunovant-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.